Bioorganic and Medicinal Chemistry Letters p. 853 - 856 (1999)
Update date:2022-08-05
Topics:
Vince, Robert
Brownell, Jay
Akella, Lakshmi B.
The inhibition of glyoxalase I enzyme to increase cellular levels of methylglyoxal has been developed as a rationale for the production of anticancer agents. Synthesis of a peptidomimetic analog of the previously prepared potent glyoxalase inhibitor, S-(p-bromobenzyl)glutathione (PBBG), was accomplished by inserting a urea linkage, NH-CO-NH, to replace the γ- glutamyl peptide bond. Thus, the target compound, γ-(L-γ-azaglutamyl)-S- (p-bromobenzyl)-L-cysteinylglycine 6, was a potent inhibitor of glyoxalase I with almost no loss of activity when compared to PBBG. However, unlike PBBG, 6 was completely resistant to enzymatic degradation by kidney homogenate or by purified γ-glutamyltranspeptidase enzyme.
View MoreDalian Synco Chemical Co., Ltd.
Contact:+86-411-83635150
Address:Rm 1004, 24, Tangshan Street, Dalian
Contact:(86) 731 88718666
Address:Room 1222, Unit 4, Building B, Shangcheng, No.47, Kaiyuan East Road.
Forsman Scientific(Beijing)co.,Ltd.
Contact:+86-10-64646565
Address:Rm No.1301, Building-2, No. A-13 Beiyuan Road, Chaoyang District Beijing, China, PR,
website:http://www.shengmaochem.com
Contact:86-27-82853423, 82819281
Address:Rm 202, A Unit Huaqiao Building No. 2, Lihuangpi Road, Wuhan, China
Chengdu Pukang Biotechnology Co., Ltd
Contact:+86-28-82550498
Address:No. 558 Rulin Road,Xinjin county,Chengdu city, China
Doi:10.1016/j.tet.2013.10.024
(2013)Doi:10.1055/s-2001-18706
(2001)Doi:10.1016/S0022-328X(00)86348-2
(1968)Doi:10.1021/ic50075a007
(1969)Doi:10.1016/S0040-4039(01)88000-X
(1969)Doi:10.1021/om990023q
(1999)